Artritis Reumatoidea,

Guardar

Certolizumab pegol in severe rheumatoid arthritis. Real-life evidence in an Argentine cohort: goal achievement (t2t) at 3 months and predictive factors.

Rodrigo Garcia Salinas 22 October, 2023

Envía un artículo